Bone tissue as the site of action of oncological drugs

Krzysztof Leśniewski-Kmak; Barbara Radecka; Maria Litwiniuk

doi:10.5114/wo.2011.23004

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2011
vol. 15

Send email

Copy url:

abstract:

Review paper

Bone tissue as the site of action of oncological drugs

Krzysztof Leśniewski-Kmak

,

Barbara Radecka

,

Maria Litwiniuk

Współcz Onkol 2011; 15 (3): 147–154

DOI: https://doi.org/10.5114/wo.2011.23004

Online publish date: 2011/07/04

View full text Get citation

PlumX metrics:

Anticancer therapy has multiple, sometimes life-threatening side effects, and their influence on bone is not seen as important. Data have been published confirming the existence of side effects chemotherapy has on bone, which affect patients’ quality of life. They influence a bone tissue not only in a direct way, but also when suppressing the activity of gonads. We have no information on the impact of drugs on bone belonging to the “targeted therapies”. There are, however, some attempts to create antibodies that target proteins involved in bone physiology. Relatively well known is the impact of anti-cancer hormone therapy on bone metabolism. The most commonly used drugs in this type of therapy are: analogues of luteinizing hormone-releasing hormone (LHRH), selective oestrogen receptor modulators (SERMs), aromatase inhibitors and antiandrogens. A group of preparations particularly connected with this issue is the bisphosphonates, entering into interaction both with bone cells and colonizing tumour cells.

keywords:

Bone tissue as the site of action of oncological drugs

Krzysztof Leśniewski-Kmak , Barbara Radecka , Maria Litwiniuk

bone tissue, chemotherapy, targeted therapy, hormonal treatment, bisphosphonates

Krzysztof Leśniewski-Kmak

,

Barbara Radecka

,

Maria Litwiniuk